

**“Molecular Characterization and the Prevalence of Urinary Tract Infection its Antibiogram with Special Reference to Drug Resistance *Mec A* gene in *Methicillin-resistant Staphylococcus aureus* (MRSA) isolates at a Tertiary Care Centre, India”**

**NASHRA AFAQ, R. SUJATHA, BIPIN KISHORE PRASAD**

Rama Medical College Hospital and Research Centre, Rama University, Mandhana, Kanpur, India.

**\*Corresponding Author- [drsujatha152@gmail.com](mailto:drsujatha152@gmail.com)**

**ABSTRACT**

**Introduction:** Most hospital visits worldwide are caused by urinary tract infections (UTIs), which are one of the primary causes of morbidity and comorbidity in patients with underlying illnesses. As *Methicillin-resistant Staphylococcus aureus* (MRSA) emerges in the community and infections with this pathogen become a common issue among UTI patients, the emergence of antibiotic-resistant bacterial strains is a serious problem and the biggest challenge in public health care.

**Aim and Objective:** To study the prevalence of urinary tract infection its bacteriological profile and the drug resistance pattern of the Patients with the molecular characterization of *MecA* gene in MRSA isolates.

**Material and Methods:** This was a Cross sectional study carried out in the Department of Microbiology at Rama Medical College Hospital and Research Centre, Mandhana Kanpur for a period of 1 year i.e, between August 2022 to August 2023. A total of 526 freshly voided mid-stream urine sample were collected in a sterile wide mouth container from the individuals preliminary routine urine tests positive for pus cells and albumin. All the urine samples were processed within one hour after the collection for aerobic bacterial culture. If delayed, samples were refrigerated and processed within 4 - 6 hours. The identification , biochemicals and the AST pattern was done according to the CLSI guidelines 2022. The DNA was extracted by using Qiagen DNA Extraction kit, which was further proceeded for the *MecA* gene detection in MRSA isolates by the conventional PCR.

**Results:** In the present study a total of 600 urine samples were received out of which 130 (21.6%) urine samples were showing significant growth for UTI. The ratio of females 79 (60.7%) were more as compared to that of the males 51 (39.2%) with the maximum age of 21-30 (40%) been affected the most followed by 31-40 (24.6%) years of age and least in the age group above 61 years of age. It was noted that the maximum number of isolates were from the gram negative isolates as compared to the gram positive isolates. It was observed that the maximum number of isolates were from the *E.coli* 60 (46.1%) followed by *Klebsiella pneumonia* 21 (16.1%) and least for *Proteus vulgaris*, *Acinetobacter baumannii*. Among the gram positive isolates the *S.aureus* (7.6%) was observed to be the maximum with 3 (30%) isolates resistant for MRSA . Our study showed a very high rate of resistance (>70%) among *E. coli* isolates to

piperacillin. Among *Klebsiella* isolates, no resistance was found for meropenem and low resistance was found for ciprofloxacin (9.52%), norfloxacin(9.52%) , and cefotaxime(23.80%) but high for nitrofurantoin (95.23%) and trimethoprim/sulfamethoxazole (42.85%) . The molecular characterization of MRSA confirmed the detection of MecA gene among the UTI patients.

**Conclusion:** To determine and elucidate the genetic mechanism behind antibiotic resistance and prevalence, phenotypic and genotypic research are required. Therefore, regular exams and strict adherence to antibiotic stewardship initiatives can minimise the cost of UTI prevention. Antibiotic abuse also highlights the need for improved prescription procedures.

**Keywords:** UTI, Antibiotic sensitivity testing, CLSI, Molecular characterization, DNA, Mec A , PCR

## INTRODUCTION

One of the most prevalent bacterial infections in regular clinical practice are urinary tract infections (UTIs), which can show clinically as anything from asymptomatic to severe sepsis. UTIs are the second most common reason for hospital visits and one of the major causes of morbidity in the general population. It also makes up around 35% of all hospital-acquired infections and is frequently the most frequent nosocomial infection in many hospitals [1].

Urinary tract infections (UTIs) are the inflammatory disorders of the urinary tract caused by the abnormal growth of pathogens [2,3]. Urinary tract infection is known to cause short-term morbidity in terms of fever, dysuria, and lower abdominal pain (LAP) and may result in permanent scarring of the kidney [4]. Urinary tract infections can be community acquired or nosocomial. Community-acquired urinary tract infections (CA-UTIs) are defined as the infection of the urinary system that takes place in one's life in the community setting or in the hospital environment with less than 48 hours of admission. Nosocomial urinary tract infections (N-UTIs) are the infection of the urinary tract that occurs after 48 hours of hospital admission, and the patient was not incubating at the time of admission or within 3 days after discharge [5].

The clinical manifestations of urinary tract infections (UTIs) vary depending on the urinary tract portion affected, the etiologic organisms, the severity of the infection, and the patient's capacity to mount an immune response to it. UTIs can be asymptomatic, acute, chronic, complicated, or uncomplicated [6]. The age of the infected individual and the location of the urinary tract infection are the main determinants of the symptoms of urinary tract infections (UTIs), which include fever, burning sensations during urination, LAP, itching, blisters and ulcers forming in the vaginal area, genital and suprapubic pain, and pyuria [3].

UTIs are caused by both Gram-negative and Gram-positive bacteria, as well as by certain fungi. There are many bacteria responsible of causing UTI infection like *E.coli*, *Klebsiella pneumoniae*, *Staphylococcus saprophyticus*, *Enterococcus faecalis*, group B *Streptococcus* (GBS), *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Candida* spp [7-10].

The incidence of urinary tract infection is increasing because patients are more frequently fitted with various urinary catheters as endourology progresses technologically. In complicated urinary tract infections and hospitalized patients, Gram positive bacteria such as MRSA are comparatively more common [11].

Patients are being fitted with different types of urinary catheters more often, which is contributing to an increase in the prevalence of urinary tract infections caused by MRSA [12]. Since MRSA is a newly discovered pathogen that can resist the effects of many antimicrobials, particularly those strains that form a biofilm in both hospitalised patients and the general public, early detection of this resistance can aid in the effective eradication of the infection. *S. aureus* develops resistance to a wide range of antibiotics due to its capacity to acquire resistance genes [13, 14].

UTI is treated with broad spectrum antibiotics empirically to start with, which are de-escalated to specific antibiotic based on information obtained from the antimicrobial susceptibility pattern of the urinary pathogens [15]. Antibiotic-resistant bacteria have emerged as a result of the widespread use of antimicrobial treatments, and the market for new medications is rising. Uropathogen distribution and antimicrobial sensitivity patterns can vary by location, thus it's important to research and gather information on them in specific contexts [16].

Antibiotic overuse has led to the emergence of drug resistance in bacteria, which is a global health concern [17, 18].

Therefore, the present study was undertaken to study the prevalence of urinary tract infection its bacteriological profile and the drug resistance pattern of the patients with the molecular characterization of MecA gene in MRSA isolates at a tertiary care centre in Uttar Pradesh.

## MATERIAL AND METHODS

This was a Cross sectional study carried out in the Department of Microbiology at Rama Medical College Hospital and Research Centre, Mandhana Kanpur for a period of 1 year i.e, between August 2022 to August 2023. A total of 600 freshly voided mid- stream urine sample were collected in a sterile wide mouth container from the individuals preliminary routine urine tests positive for pus cells and albumin. All the urine samples were processed within one hour after the collection for aerobic bacterial culture. If delayed, samples were refrigerated and processed within 4 - 6 hours.

The patients presenting or highly suspicious of having UTIs and ready to give consent were included in the study. Any patient who was terminally ill, who fails to give urine samples, with a history of antibiotic administration in the last two weeks and any female who was in their menstruation period were excluded from the study [19].

The patients demographic details including age, gender, tribe, residence, level of education, and history of medical conditions were included in the study.

## **Microscopic Study**

One of the diagnosis criteria of UTI was based on microscopic findings of more than 10 pus cells/ high power field (40×) in urine were included in the study.

## **Collection and process of urine samples**

Mid-stream urine samples were collected in a sterile container and were processed within 2 h of collection time. These urine samples were also centrifuged and urine sediment was used for direct microscopic examination of red blood cells (RBCs), leukocytes, epithelial cell, casts, crystals, and parasites. In the normal urine sediment, a few count of RBCs, pus cells (0–5/high power field), and epithelial cells may present. Epithelial cell count reported as “few,” “moderate,” or “many” per low-power field.

## **Isolation and Identification of Uropathogens**

The Urine sample was inoculated on a standard culture media Cystine–Lactose– Electrolyte-Deficient (CLED) agar using a calibrated (1 µL) loop.

Culture plates were incubated at 35–37°C ambient air incubator for 18 h. After the allocated time period, the culture plates were visualized for the presence of bacterial colonies. They were reported as significant or non-significant growth on the basis of colony count method. Isolated colonies were further characterised based on cultural characteristics by growing on differential media, such as MacConkeys agar and blood agar [20]. Further, the isolates were identified by cultural, morphological and biochemical tests. The method used in the identification and characterisation of isolated bacteria included Gram staining, motility test and biochemical tests like, TSI and IMViC according to Cheesbrough [21, 22, 23]. Isolated and characterized uropathogens were then preserved in nutrient broth containing 25% glycerol at –20°C.

The plates were incubated at 37°C for 24 hrs and extended to 48 hrs in culture (growth) negative cases. The identification , biochemicals and the AST pattern was done according to the CLSI guidelines 2022 [24]. All chemicals required for culture media and reagents were procured from HiMedia laboratories Pvt Ltd., Mumbai.

**Molecular Detection of MecA Gene by Polymerase Chain Reaction (PCR) in Methicillin resistant *Staphylococcus aureus***

Bacterial DNA was extracted by QIAamp DNA Kit by following manufactures guidelines. *S. aureus* previously extracted DNA was used for the amplification of Mec A gene. The primers were purchased from “Saha gene” and was reconstituted with sterile double distilled water based on the manufacturer’s instruction.



**Figure No.1: The DNA Extraction kit    Figure No.2: The Reagents used for the DNA Extraction**



**Figure No.3: The MecA gene primers from the Saha gene    Figure No. 4: Run of Amplified product**

All *S. aureus* isolates that were resistant to cefoxitin 30 µg and positive on ORSAB examination were then subjected to a PCR test to detect the presence of the *mecA* gene [25]. The DNA extraction process was carried out according to the QIAamp DNA Mini Kit protocol, where previously the isolates were purified on MSA (HiMedia Pvt. Ltd, M118) and inoculated on MHA (Oxoid, CM0337).

Gene	Primer	Base Pair	Reference
MecA	F: 5'-AAA ATC GAT GGT AAA GGT TGG C-3'  R: 5'-AGT TCT GCA GTA CCG GAT TTG C-3'.	533	[26]

**Table No. 1: Primer used for the Meca gene detection  
Molecular Characterization of Meca gene**


The PCR master mix used GoTaq Green Master Mix (Promega, 9PIM712) which is a ready-to-use solution mixture containing Taq DNA polymerase, dNTPs, MgCl<sub>2</sub>, and a reaction buffer. DNA was amplified using a Thermal Cycler T100 machine (Bio-Rad, 186-1096) for 40 cycles in 25 µl of the reaction mixture with the following steps: denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 min with a final extension at 72°C for 5 min. A total of 10 µl of PCR product were analyzed by 2% agarose gel electrophoresis, and the gel was visualized under ultraviolet light [27]. A positive test indicated a PCR product in the 533-base pair (bp) band [27].

**RESULTS**

A total of 600 urine samples were received in the Microbiology Laboratory at RMCH&RC out of which 130 (21.6%) urine samples were showing significant growth for UTI [Table No. 2]. The ratio of females 79 (60.7%) were more as compared to that of the males 51 (39.2%) [Table no. 3] . The maximum age of 21-30 (40%) was affected the most followed by 31-40 (24.6%) years of age and least in the age group above 61 years of age [Table no.4].

Type of Clinical Isolates	Number of Isolates	Percentage
Urine samples	600	78.3%
Significant growth for UTI	130	21.6%


**Table No. 2 : Samplewise distribution of the clinical isolates**



**Graph No. 1: Graphical Representation of Samplewise distribution of the clinical isolates**

Gender	Total no. of Cases studies (N=130)	Percentage
Male	51	39.2%
Female	79	60.7%

**Table No. 3: Gender wise distribution of the UTI cases**



**Graph No. 2: Graphical Representation of Genderwise distribution of the UTI cases**

S.N.	Age group (Years)	Male N= 51	Female N= 79	Percentage (%)
1.	0-10	-	-	-
2.	11-20	8	11	14.6%
3.	21-30	18	34	40%
4.	31-40	14	18	24.6%
5.	41-50	5	7	9.2%
6.	51-60	3	5	6.1%
7.	61-70	2	4	4.6%
8.	≤ 80	1	-	0.7%

**Table No. 4 : Agewise distribution of the UTI cases**


It was noted that the maximum number of isolates were from the gram negative isolates as compared to the gram positive isolates.

It was observed that the maximum number of isolates were from the *E.coli* 60 (46.1%) followed by *Klebsiella pneumonia* 21 (16.1%) and least for *Proteus vulgaris*, *Acinetobacter baumannii*, *Staphylococcus saprophyticus* with 1 (0.76%). Among the gram positive isolates the *S.aureus* (7.6%) was observed to be the maximum with 3 (30%) isolates resistant for MRSA isolates [Table no.5].



Type of Organism Isolated	No. of Isolates	Percentage
<i>Escherichia coli</i>	60	46.1%
<i>Klebsiella pneumoniae</i>	21	16.1%
<i>Proteus mirabilis</i>	16	12.3%
<i>Pseudomonas aeruginosa</i>	10	7.6%
<i>Citrobacter freundii</i>	4	3%
<i>Klebsiella oxytoca</i>	3	2.3%
<i>Proteus vulgaris</i>	1	0.76%
<i>Acinetobacter baumannii</i>	1	0.76%
<i>Enterococcus faecalis</i>	3	2.3%
<i>Staphylococcus saprophyticus</i>	1	0.76%
<i>Staphylococcus aureus</i>	10	7.6%
<b>Total</b>	<b>130</b>	<b>100%</b>

**Table No. 5: The Frequency of bacteria isolated from the UTI cases**



**Graph No. 3: Graphical Representation of Frequency of bacteria isolated from the UTI cases**

In the present study it was also observed that high degree of drug resistance among bacterial isolates was observed . Our study showed a very high rate of resistance (>70%) among *E. coli* isolates to piperacillin. Among *Klebsiella* isolates, no resistance was found for meropenem and low resistance was found for ciprofloxacin (9.52%), norfloxacin(9.52%) , and cefotaxime(23.80%) but high for nitrofurantoin (95.23%) and trimethoprim/sulfamethoxazole (42.85%) .

Antibiotics	<i>Escherichia coli</i>	<i>Klebsiella pneumoniae</i>	<i>Proteus mirabilis</i>	<i>Pseudomonas aeruginosa</i>
Ampicillin	53 (88.3%)	21 (100%)	11 (68.75%)	IR
Amoxicillin/clavulanic acid	29 (48.3%)	13 (61.9%)	4 (25%)	IR

Piperacillin	50 (83.3%)	20 (94%)	4 (25%)	10 (100%)
Piperacillin/tazobactam	19( 31.6%)	7 (33.33%)	4 (25%)	10(100%)
Cefalotin	42 (70%)	7 (33.33%)	5 (31.25%)	IR
Cefuroxime	6 (10%)	7 ( 33.33%)	5 (31.25%)	IR
Cefoxitin	5 (8.3%)	2(9.52%)	4 (25%)	IR
Cefpodoxime	5 (8.3%)	5 (23.80%)	4 (25%)	IR
Cefotaxime	2(3.3%)	5 (23.80%)	4 (25%)	IR
Ceftazidime	3 (5%)	5 (23.80%)	4 (25%)	10 (100%)
Cefepime	3 (5%)	5 (23.80%)	4 (25%)	8 (80%)
Meropenem	5(8.3%)	0	0	5 (50%)
Amikacin	9 (15%)	3 (14.28%)	0	2 (20%)
Gentamicin	5 (8.3%)	3 (14.28%)	0	2 (20%)
Tobramycin	10 (16.6%)	3 (14.28%)	0	2 (20%)
Ciprofloxacin	19 (31.6%)	2 (9.52%)	0	2 (20%)
Norfloxacin	19 (31.6%)	2 (9.52%)	4 (25%)	2 (20%)
Nitrofurantoin	5 (8.3%)	20 (95.23%)	IR	-
Trimethoprim/sulfamethoxazole	30 (50%)	9 (42.85%)	4 (25%)	IR

<b>Total number of isolates</b>	<b>60</b>	<b>21</b>	<b>16</b>	<b>10</b>

**Table No.6 : Number (%) of common Gram-negative urinary pathogens resistant (R) to antimicrobial agents**

<b>Antibiotics</b>	<i>Citrobacter freundii</i>	<i>Klebsiella oxytoca</i>	<i>Proteus vulgaris</i>	<i>Acinetobacter baumannii</i>
Ampicillin	IR	IR	IR	IR
Amoxicillin/clavulanic acid	IR	3 (100%)	1 (100%)	IR
Piperacillin	4 (100%)	3 (100%)	1 (100%)	0
Piperacillin/tazobactam	1 (25%)	3 (100%)	1 (100%)	0
Cefalotin	IR	3 (100%)	IR	IR
Cefuroxime	IR	IR	IR	IR
Cefoxitin	IR	2(66.6%)	1 (100%)	IR
Cefpodoxime	IR	3 (100%)	1 (100%)	-
Cefotaxime	2 (50%)	3 (100%)	1 (100%)	0
Ceftazidime	2 (50%)	3(100%)	1 (100%)	0
Cefepime	1 (25%)	3 (100%)	1 (100%)	0
Meropenem	0	2 (66.6%)	0	0

Amikacin	2 (50%)	3 (100%)	0	0
Gentamicin	2 (50%)	2(66.6%)	0	0
Tobramycin	2 (50%)	3 (100%)	0	0
Ciprofloxacin	4(100%)	3 (100%)	1 (100%)	0
Norfloxacin	4 (100%)	3 (100%)	1 (100%)	0
Nitrofurantoin	2( 50%)	2 (66.6%)	IR	-
Trimethoprim/sulfame thoxazole	1 (25%)	2 (66.6%)	1 (100%)	1 (100%)
<b>Total number of isolates</b>	<b>4</b>	<b>3</b>	<b>1</b>	<b>1</b>

**Table No. 7: Number (%) of less common Gram-negative urinary pathogens resistant (R) to antimicrobial agents**


Antibiotics	<i>Enterococcus faecalis</i>	<i>Staphylococcus saprophyticus</i>	<i>Staphylococcus aureus</i>
Benzyl penicillin	3 (100%)	1 (100%)	10 (100%)
Cefoxitin	-	0	3 (30%)
Gentamicin	IR	0	0
Tobramycin	IR	0	0
Levofloxacin	0	0	3 (30%)
Clindamycin	IR	0	0
Linezolid	0	0	0

Teicoplanin	0	0	0
Vancomycin	0	0	0
Fosfomycin	3 (100%)	IR	0
Nitrofurantoin	0	0	0
Rifampicin	3(100%)	0	0
Trimethoprim/Sulfame thoxazole	IR	0	0
<b>Total number of isolates</b>	<b>3</b>	<b>1</b>	<b>10</b>


**Table No.8 : Number (%) of common Gram-positive urinary pathogens resistant (R) to antimicrobial agents**

The frequency of *Acinetobacter*, *Citrobacter*, *Klebsiella* and *proteus* is mentioned in Table 7 due to their clinical relevance. The number (percentage) of common Gram-negative urinary pathogens resistant (R) to antimicrobial agents is shown in Table 7 and Table 8 refer to the Gram positive isolate .

The DNA Extraction was performed by the Qiagen DNA kit and the DNA was isolated from the samples. From the 9 isolates of *S.aureus*, there were 3 isolates observed positive for MRSA. The DNA Extraction and the gene detection of the isolate 3 isolates was performed for the detection of Mec A gene among the MRSA isolates.



**Figure No. 5: The DNA Extraction**



**Figure No. 6: Photograph of amplified MecA gene in MRSA; the amplified DNA band size was obtained 533bp, L1 corresponds to the Negative control and L2 corresponds to the Positive control, L3 corresponding to 100bp ladder used; Lane 4-6 are the sample positive for MecA**

In the current study it was observed that there were 3 isolates found positive for the MecA gene.

```
GTTGTAGTTGTCGGGTTTGGTATATATTTTTATGCTTCAAAGATAAAGAAATTAAT
AATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAAAGATAGCAGT
TATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAAT
```

```
ATATAATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAG
TATCTAAAAATAAAAAACGAGTAGATGCTCAATATAAAATTA AACAAACTACGGT
AACATTGATCGCAACGTTCAATTTAATTTTGTAAAGAAGATGGTATGTGGAAG
TCTAAAAAGCATGTAAAAGAATTTGCGACCAGATTGCAAATCTGCAACGAGCTTT
GGGTTTACTCCCCCGGTGGAGATGGATATAAAAATGCTCAAAAAGTACCACCAC
TATATTTTCCTAAGAAGCTATCAAATAATTATAATCA
```

**Figure No.7: Obtained gene sequences of MecA gene in *S. aureus***

## DISCUSSION

UTIs are among the most serious infections that are reported worldwide. Many conditions, including urethritis, cystitis, and pyelonephritis, are classified as UTIs. 50% of women had a history of urinary tract infections, according to reports. UTIs are serious health problems that affect 150 million people worldwide each year [28]. According to reports, bacteria are most frequently responsible for UTIs. Although *Staphylococcus aureus* is not known to be a prominent bacterium that causes UTIs, recent studies have found that its prevalence has grown [29].

In the present study the prevalence of UTI was found to be 21.6%. This finding was similar to the study performed by the other authors Ahmad S et al and Suhail A. et al., where the prevalence was found to be 20.54% and 32% respectively [30,31].

In the current study the maximum number of isolates were from the Females 79 (60.7%) as compared to that of the males 51 (39.2%). This study was similar to the study by Suhail A. et al, and Martin Odoki et al., in 2019 where the ratio of females was more as compared to the males [31] [32].

It was noted that the maximum number of isolates were from the gram negative isolates as compared to the gram positive isolates. It was observed that the maximum number of isolates were from the *E.coli* 60 (46.1%) followed by *Klebsiella pneumonia* 21 (16.1%) and least for *Proteus vulgaris*, *Acinetobacter baumannii* with 1 (0.76%). Among the gram positive isolates the *S.aureus* (7.6%) was observed to be the maximum with 3 (30%) isolates resistant for MRSA. Similar study was performed by the other research workers where among 206 bacterial isolates obtained from 417 urine samples, majority of the isolates (99%) were Gram negative bacteria which included *Escherichia coli* (56.79%), *Klebsiella sps* (19.9%), *Pseudomonas sps* (6.3%), *Proteus sps* (5.8%), *Enterobacter sps* (3.8%), *Citrobacter sps* (1.4%), *Enterococcus sps* (0.9%), and other NFGNB (4.8%) [33].

In the present study it was found that antimicrobial resistance was seen both in Gram-positive and Gram-negative bacteria. Multiple resistances were high among the isolated urinary pathogens.



One important human pathogen that causes the majority of nosocomial and hospital-acquired illnesses is *Staphylococcus aureus*. Numerous illnesses, such as UTIs, respiratory and soft tissue infections, endocarditis, osteomyelitis, and endocarditis, are brought on by it. Severe antibiotic resistance has emerged in the bacterium. Based on clinical observations, approximately half of the *S. aureus* isolates exhibited total resistance to the penicillin and cephalosporin antibiotic groups; these strains were referred to be methicillin-resistant *S. aureus* (MRSA). Due to hospitalisation and treatment costs, MRSA strains produced complex disorders over longer periods of time and at a higher cost [34].

In the present study it was observed that the rate of MRSA among the UTI cases were 2.3%. This study was in support with the study performed by the other author Khaleel R et al., [35] where 7.7% of the urine specimens of hospitalized patients who suffered from UTIs were positive for the MRSA strains. MRSA isolates displayed a boost resistance rate toward erythromycin, ceftaroline, penicillin, gentamicin, and ciprofloxacin antimicrobial agents. Additionally, MRSA isolates harbored a boost distribution of beta lactamase gene *MecA* antimicrobial resistance-encoding genes. It seems that the antimicrobial-resistant MRSA isolates may be an emerging cause of UTIs in Uttar Pradesh. Similarly, Lunacek et al [36] labelled that the MRSA prevalence amongst urine specimens in Austria was 4.06%. They disclosed that MRSA isolates were resistant toward cephalosporin, aminopenicillin, penicillin G, carbapenem, and  $\beta$ -lactamase antimicrobial agents. They also presented that catheter utilization is the most critical risk factor for MRSA occurrence in UTIs. An Irish survey [37] described that the prevalence of MRSA strains was 27.9%. Besides, MRSA isolates of the urine specimens displayed the uppermost resistance rate toward flucloxacillin (100%), co-amoxiclav (100%), and ciprofloxacin (98%).

Our study showed a very high rate of resistance (>70%) among *E. coli* isolates to piperacillin. Among *Klebsiella* isolates, no resistance was found for meropenem and low resistance was found for ciprofloxacin (9.52%), norfloxacin(9.52%) , and cefotaxime(23.80%) but high for nitrofurantoin (95.23%) and trimethoprim/sulfamethoxazole (42.85%) . This resistance is most likely due to the massive use of third-generation cephalosporins and fluoroquinolone antibiotics in UTIs patients. The high resistance in trimethoprim/sulfamethoxazole susceptibility pattern may be due to non-judicious use and over-the-counter selling of this antibiotic [31].

It is well known that the antibiotic susceptibility of uropathogenic bacteria varies over time and between geographical locations [38]. The effectiveness of the top antimicrobials against the uropathogens in this study that have a low resistance rate (overall resistance%) is discussed here. The best antibiotics for Gram-negative organisms were cefepime, gentamicin, amikacin, tobramycin, and meropenem. Antimicrobials with a moderate resistance risk included ceftazidime, cefpodoxime, piperacillin/tazobactam, cefuroxime, ciprofloxacin, cefotaxime, ceftazidime, and norfloxacin. Notably, a high rate of resistance was discovered to be present

against ampicillin, amoxicillin/clavulanic acid piperacillin, nitrofurantoin, trimethoprim/sulfamethoxazole, and cefuroxime.

The current finding is similar to other reports which suggest that gram negative bacteria, particularly *E. coli* was the commonest pathogens isolated from patients with UTI [39,40]. The incidence of *E. coli* in our study was higher when compared with the Nigerian studies reporting 42.10% [41] and 51% [42]. Most of the studies conducted in Africa and Arab countries showed less than 50% isolation of *E. coli* from the UTI patients but reported a higher percentage (29%) of *S. aureus* as second most frequently isolated bacteria from UTI cases. Reports from other developing or developed countries were the isolation of Gram positive bacteria as uropathogen is very low <10% [43,44].

In contrast, the antimicrobial sensitivity pattern of antimicrobials for Gram-positive organisms shows linezolid, teicoplanin, vancomycin, cefalotin screen, moxifloxacin, nitrofurantoin, and levofloxacin were sensitive however there were 33.33% resistance observed for ceftiofuran.

The overall proportion of MRSA among isolated *S. aureus* in this study was elevated from previous studies conducted in Iran (25.8%) [45] Nepal (30.8%) [46] Uganda (33.3%) [47] and Nigeria (13%) [48]. This increased proportion of MRSA might be due to differences in geographic area, MRSA becoming a global nosocomial pathogen with rapid spread to health care as well as community and urinary tract infection associated factors may also play an important role in increasing the prevalence of MRSA in the community.

Both the aetiology of UTI-causing bacteria and their resistance to antibiotics are changing over time and amongst various nations [49].

Correct identification of the causal microorganism is essential for the successful treatment of UTI patients. Failing to do so will not only cause the patient to experience problems and extend the course of the illness, but it will also encourage the unfavourable effects of bacterial resistance as a result of the careless use of unnecessary antibiotics.

Continuous monitoring of the etiology of infections and antibiotic resistance pattern is essential not only for selecting appropriate antibiotics for empirical therapy but also for reducing the overuse/misuse of antibiotics.

## CONCLUSION

The abuse of antibiotics has led to the emergence of drug resistance in bacteria, which is a global health concern. Therefore, in order to guarantee proper treatments, it is necessary to be aware of the changes in the spectrum of drug resistance.

The high prevalence of *S. aureus* and MRSA infections should be decreased by using the effective infection prevention and control techniques. To determine and elucidate the genetic mechanism underlying antibiotic resistance and prevalence, further phenotypic and genotypic research is required. Nonetheless, more investigations ought to be conducted to evaluate additional MRSA epidemiology characteristics in UTIs.

## ACKNOWLEDGEMENTS:

The authors are thankful to the Principal and Director of the Rama Medical College Hospital and Research Centre, Kanpur (India) for providing facilities and permission to perform this original work at this Institute.

## Declaration:

**Source for this Research Fund:** None

**Conflict of Interest:** None

**Consent for publication:** We have consent for the publication of this paper.

## REFERENCES

1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am.* 2014; 28:1–13.
2. D. Prakash and R. S. Saxena, “Distribution and antimicrobial susceptibility pattern of bacterial pathogens causing urinary tract infection in Urban Community of Meerut City, India,” *ISRN Microbiology.* 2013; Article ID 749629, 13 pages.
3. O. Amali, M. D. Indinyero, E. U. Umeh, and N. O. Awodi, “Urinary tract infections among female students of the university of agriculture, Makurdi, Benue State, Nigeria,” *Internet Journal of Microbiology.* 2009; vol. 7, no. 1, pp. 1–5.
4. Hooton TM. Uncomplicated urinary tract infection. *N Engl J Med.* 2012; 366:1028–1037.
5. V. Lacovelli, G. Gaziev, L. Topazio, P. Bove, G. Vespasiani, and A. E. Finazzi, “Nosocomial urinary tract infections: a review,” *Urologia.* 2014; 81(4) , pp. 222–227, 2014.
6. O. Olowe, B. Ojo-Johnson, O. Makanjuola, R. Olowe, and V. Mabayoje, “Detection of bacteriuria among human immunodeficiency virus seropositive individuals in Osogbo, south-western Nigeria,” *European Journal of Microbiology and Immunology.* 2015; vol. 5, no. 1, pp. 126–130.
7. Hooton TM. Uncomplicated urinary tract infection. *New Engl J Med.* 2012; 366:1028–1037.
8. Nielubowicz GR, Mobley HL. Host–pathogen interactions in urinary tract infection. *Nature Rev Urol.* 2010; 7:430–441.
9. Kline KA, Schwartz DJ, Lewis WG, Hultgren SJ, Lewis AL. Immune activation and suppression by group B *Streptococcus* in a murine model of urinary tract infection. *Infect Immun.* 2011; 79:3588–3595.
10. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. *Am J Med.* 2002; 113 (Suppl 1A):14S–19S.
11. Bereket W, Hemalatha K, Getenet B. Update on bacterial nosocomial infections. *Eur Rev Med Pharmacol Sci.* 2012; 16(8):1039–1044.

12. Shahmoradi M, Faridifar P, Shapouri R, Mousavi SF, Ezzedin M, Mirzaei B. Determining the biofilm forming gene profile of staphylococcus aureus clinical isolates via multiplex colony PCR method. *Rep Biochem Mol Biol.* 2019; 7(2):181–188.
13. Jia P, Zhu Y, Li X, Kudinha T, Yang Y, et al. High prevalence of extended-spectrum beta-lactamases in *Escherichia coli* strains collected from strictly defined community-acquired urinary tract infections in adults in china: a multicenter prospective clinical microbiological and molecular study. *Front Microbiol.* 2021; 12:1–12.
14. Soto SM. Importance of biofilms in urinary tract infections: new therapeutic approaches. *Adv Biol.* 2014; doi:10.1155/2014/157895
15. Yang B, Yang F, Wang S, Wang Q, Liu Z, et al. Analysis of the spectrum and antibiotic resistance of uropathogens in outpatients at a tertiary hospital. *J Chemother.* 2018; 30:145–149.
16. Khan MI, Xu S, Ali MM, Ali R, Kazemi A, Akhtar N, et al. Assessment of multidrug resistance in bacterial isolates from urinary tract infected patients. *J Radiat Res Appl Sci* 2020; 13: 267–275.
17. Seifu WD, Gebissa AD. Prevalence and antibiotic susceptibility of uropathogens from cases of urinary tract infections (UTI) in Shashemene referral hospital, Ethiopia. *BMC Infect Dis* 2018; 18: 30.
18. Prasada S, Bhat A, Bhat S, Shenoy Mulki S, Tulasidas S. Changing antibiotic susceptibility pattern in uropathogenic *Escherichia coli* over a period of 5 years in a tertiary care center. *Infect Drug Resist.* 2019; 12:1439–1443.
19. Manjula N. G., Girish C. Math., Shripad A. Patil, Subhashchandra M. Gaddad, Channappa T. Shivannavar. Incidence of Urinary Tract Infections and Its Aetiological Agents among Pregnant Women in Karnataka Region. *Advances in Microbiology.* 2013; 3, 473-478.
20. Beckford-Ball, “Related Articles, Management of Sus- pected Bacterial Urinary Tract Infection,” *Nursing Times.* 2006; 102( 32): 25-26.
21. M. Cheesbrough, “Medical Laboratories Manual for Tropical Countries,” Butterworth-Heinemann, Cambridge, 2002.
22. M. Cheesbrough, “District Laboratories Manual for Tro- pical Countries,” Cambridge University Press, Cambridge, 2004.
23. E. Giron, C. Rioux, C. Brun-Buisson and B. Lobel, “In- fection Committee of the French Association of Urology. The Postoperative Bacteriuria Score: A New Way to Pre- dict Nosocomial Infection after Prostate Surgery,” *Infec- tion Control and Hospital Epidemiology,* 2006; 27( 8): 847-854.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 28th ed. M100. Wayne: Clinical and Laboratory Standards Institute (CLSI); 2022. p. 38.

25. Ho PL, Liu MC, Tong MK, *et al.*: Evaluation of disk diffusion tests and agar screening for predicting *mecA*-mediated oxacillin resistance in *Staphylococcus lugdunensis* is revealed a cefoxitin-susceptible, *mecA*-positive *S. lugdunensis* clonal complex 27 clone. *J. Glob. Antimicrob. Resist.* 2020; 20: 260–265.
26. Nam LV, Quyet D, Hung PN, *et al.*: Antibiotic Resistance Profile and Methicillin-Resistant Encoding Genes of *Staphylococcus aureus* Strains Isolated from Bloodstream Infection Patients in Northern Vietnam. *Open Access Maced J. Med. Sci.* 2019; 7(24): 4406–4410.
27. Rahmaniar RP, Yunita MN, Effendi MH, *et al.*: Encoding gene for methicillin-resistant *Staphylococcus aureus*(MRSA) isolated from nasal swab of dogs. *Indian Vet. J.* 2020; 97(2): 37–40.
28. Onanuga A, Awhowho GO. Antimicrobial resistance of *Staphylococcus aureus* strains from patients with urinary tract infections in Yenagoa, Nigeria. *J Pharm Bioal Sci.* 2012; 4:226. doi: 10.4103/0975-7406.99058.
29. Akortha EE, Ibadin OK. Incidence and antibiotic susceptibility pattern of *Staphylococcus aureus* amongst patients with urinary tract infection (UTI) in UBTH Benin City, Nigeria. *Afr J Biotechnol.* 2008;7:1637-40. doi: 10.5897/AJB08.176
30. Ahmad S, Ahmad F. Urinary tract infection at a specialist hospital in Saudi Arabia. *Bangladesh Med Res Counc Bull.* 1995;21:95-8.
31. Syed Suhail Ahmed, Ali Shariq, Abdulaziz Ajlan Alsalloom, Ibrahim H. Babikir, Badr N. Alhomoud. Uropathogens and their antimicrobial resistance patterns: Relationship with urinary tract infections. *International Journal of Health Sciences.* 2019; Vol. 13, Issue 2 .
32. Martin Odoki , Adamu Almustapha Aliero , Julius Tibyangye , Josephat Nyabayo Maniga, Eddie Wampande, Charles Drago Kato, Ezera Agwu, and Joel Bazira . Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda *International Journal of Microbiology.* 2019, Article ID 4246780, 8 pages
33. August SL, De Rosa MJ. Evaluation of the prevalence of urinary tract infection in rural panamanian women. *PLoS One* 2012;7:e47752
34. Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, Zimmer SM, Potter MA, Macal CM, Lauderdale DS, Miller LG. The economic burden of community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA). *Clin Microbiol Infect.* 2013; 19:528-36.
35. Raghad Abdulsalam Khaleel ID , Narjes Alfuraiji ID , Balsam Waleed Hussain , Maadh Fawzi Nassar ID , Farnoosh Ebrahimzadeh ID. Methicillin-resistant *Staphylococcus aureus* in urinary tract infections; prevalence and antimicrobial resistance. *J Renal Inj Prev.* 2022; 11(1): e08.

36. Lunacek A, Koenig U, Mrstik C, Radmayr C, Horninger W, Plas E. Unexpected multidrug resistance of methicillin-resistant *Staphylococcus aureus* in urine samples: A single-center study. *Kor J Urol*. 2014; 55:349.
37. Looney AT, Redmond EJ, Davey NM, Daly PJ, Troy C, Carey BF, Cullen IM. Methicillin-resistant *Staphylococcus aureus* as a uropathogen in an Irish setting. *Medicine*. 2017; 7;96:e4635. doi: 10.1097/MD.0000000000004635.
38. D. Adukauskienė, I. Cicinskaite, A. Vitkauskienė, A. Macas, R. Tamosiunas, and A. Kinderyte, "Hospital acquired urinary tract infections," *Medicina (Kaunas)*. 2006; 45(12): 957–964.
39. A. K. Onifade, F. O. Omoya and D. V. Adegunloye, "Incidence and Control of Urinary Tract Infections among Pregnant Women Attending Antenatal Clinics in Government Hospitals in Ondo State, Nigeria," *Journal of Food Agriculture and Environment*. 2005; Vol. 3, No. 1: pp. 37-38.
40. E. E. A. Okonofua and B. N. Okonofua, "Incidence and Pattern of Asymptomatic Bacteriuria of Pregnancy in Nigerian Women," *The Nigerian Medical Practitioner*. 1989; Vol. 17: 354-358.
41. I. O. Okonko, L. A. Ijandipe, O. A. Ilusanya, *et al.*, "Incidence of Urinary Tract Infection (UTI) among Pregnant Women in Ibadan, South-Western Nigeria," *African Journal of Biotechnology*. 2009; Vol. 8, No. 23: 6649- 6657.
42. P. I. Nwanze, L. M. Nwaru, S. Oranusi, U. Dimkpa, M. U. Okwu, B. B. Babatunde, A. Anake, W. Jatto and C. E. Asagwara, "Urinary Tract Infection in Okada Village: Prevalence and Antimicrobial Susceptibility Pattern," *Scientific Research and Essays*. 2007; Vol. 2, No. 4: . 112-116.
43. M. Akram, M. Shahid and A. U. Khan, "Aetiology and Antibiotic Resistance Patterns of Community Acquired Urinary Tract Infections in JNMC Hospital Aligarh, India," *Annals of Clinical Microbiology and Antimicrobials*. 2007; Vol. 6, :4-10.
44. E. Mahesh, D. Ramesh, V. A. Indumathi *et al.*, "Complicated Urinary Tract Infection in a Tertiary Care Center in South India," *Al Ameen Journal of Medical Science*. 2010; Vol. 3, No. 2, :120-127.
45. Rahimi F, Katouli M, Karimi S. Biofilm production among methicillin resistant *Staphylococcus aureus* strains isolated from catheterized patients with urinary tract infection. *Microb Pathog*. 2016; 98:69–76.
46. Shrestha B, Pokhrel B, Mohapatra T. Study of nosocomial isolates of *Staphylococcus aureus* with special reference to methicillin resistant *S. aureus* in a tertiary care hospital in Nepal. *Nepal Med Coll*. 2009; 11(2):123–126.
47. Bahati J, Stephen BM, Joseph N, Asiphos O, Musa K, Taseera K. Prevalence and bacteriology of symptomatic urinary tract infection among pregnant women at Mbarara Regional Referral Hospital, South-western Uganda. *J Interpers Violence*. 2020; 35(17–18):3286–3307.

48. Mofolorunsho CK, Ocheni M, Omatola CA, Agieni AG. Staphylococcus Aureus prevalence and antibiotic susceptibility profile in anyigba, north-central Nigeria. *Am J Infect Dis.* 2015;11(4):93.
49. Hamdan HZ, Kubbara E, Adam AM, Hassan OS, Suliman SO, Adam I, *et al.* Urinary tract infections and antimicrobial sensitivity among diabetic patients at Khartoum, Sudan. *Ann Clin Microbiol Antimicrob* 2015; 14:26.